Cytokinetics Inc
CYTKNasdaqCIK 1061983HealthcareFiscal year ends Dec 31
Reports and events: 530 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-2813:21 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-372456 |
| 2026-08-1313:25 ET | 8-K | 8.01 Other events | 0001193125-26-348060 |
| 2026-08-0620:30 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-338217 |
| 2026-08-0620:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338021 |
| 2026-05-2720:00 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-241840 |
| 2026-05-0820:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-214606 |
| 2026-05-0520:12 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-206420 |
| 2026-05-0520:06 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-206364 |
| 2026-05-0520:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-206360 |
| 2026-04-1720:05 ET | DEF 14A | Proxy statementPeriod 2026-05-27 | 0001140361-26-015364 |
| 2026-02-2621:01 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-076495 |
| 2026-02-2421:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-067012 |
| 2026-02-1712:30 ET | 8-K | 8.01 Other events | 0001193125-26-053049 |
| 2025-12-1921:01 ET | 8-K | 8.01 Other events | 0001193125-25-326778 |
| 2025-12-1213:54 ET | 8-K | 8.01 Other events | 0001193125-25-316904 |
| 2025-11-1421:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-282889 |
| 2025-11-0521:31 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-267059 |
| 2025-11-0521:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-266842 |
| 2025-09-2223:22 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-209437 |
| 2025-09-1620:08 ET | 8-K | 8.01 Other events | 0001193125-25-204991 |
| 2025-09-0821:02 ET | 8-K/A | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-113599 |
| 2025-09-0321:34 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-112570 |
| 2025-09-0221:20 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-112564 |
| 2025-08-2011:57 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-25-110368 |
| 2025-08-0720:30 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-105108 |
| 2025-08-0720:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-104962 |
| 2025-05-1622:39 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-072965 |
| 2025-05-0620:30 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-064529 |
| 2025-05-0620:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-064432 |
| 2025-05-0120:15 ET | 8-K | 8.01 Other events | 0000950170-25-061847 |
| 2025-04-1011:30 ET | DEF 14A | Proxy statementPeriod 2025-05-14 | 0001140361-25-013167 |
| 2025-03-1011:30 ET | 8-K | 7.01 Regulation FD disclosure | 0000950170-25-035914 |
| 2025-02-2722:05 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-029206 |
| 2025-02-2721:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-029017 |
| 2025-02-1112:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-25-017458 |
| 2024-12-1621:38 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-24-136695 |
| 2024-11-1911:02 ET | 8-K | 1.01 Entry into a material agreement | 0000950170-24-128266 |
| 2024-11-0721:05 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-123283 |
| 2024-11-0721:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-24-123277 |
| 2024-08-1520:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-24-097556 |
| 2024-08-0920:05 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-094743 |
| 2024-08-0820:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093855 |
| 2024-06-0721:13 ET | 8-K | 8.01 Other events | 0001193125-24-157531 |
| 2024-06-0514:02 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-069098 |
| 2024-05-2820:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-148077 |
| 2024-05-2220:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-144965 |
| 2024-05-2220:13 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 2.03 New direct financial obligation | 0001193125-24-144956 |
| 2024-05-1722:56 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-24-061275 |
| 2024-05-1320:09 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-058654 |
| 2024-05-1020:05 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-057805 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:03 ET. Listed shows no prices and gives no investment advice.